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Abstract
Background: Meiotic recombination ensures proper segregation of homologous chromosomes and creates
genetic variation. In many organisms, recombination occurs at limited sites, termed ‘hotspots’, whose positions in
mammals are determined by PR domain member 9 (PRDM9), a long-array zinc-finger and chromatin-modifier
protein. Determining the rules governing the DNA binding of PRDM9 is a major issue in understanding how it
functions.
Results: Mouse PRDM9 protein variants bind to hotspot DNA sequences in a manner that is specific for both
PRDM9 and DNA haplotypes, and that in vitro binding parallels its in vivo biological activity. Examining four
hotspots, three activated by Prdm9Cst and one activated by Prdm9Dom2, we found that all binding sites required the
full array of 11 or 12 contiguous fingers, depending on the allele, and that there was little sequence similarity
between the binding sites of the three Prdm9Cst activated hotspots. The binding specificity of each position in the
Hlx1 binding site, activated by Prdm9Cst, was tested by mutating each nucleotide to its three alternatives. The 31
positions along the binding site varied considerably in the ability of alternative bases to support binding, which
also implicates a role for additional binding to the DNA phosphate backbone.
Conclusions: These results, which provide the first detailed mapping of PRDM9 binding to DNA and, to our
knowledge, the most detailed analysis yet of DNA binding by a long zinc-finger array, make clear that the binding
specificities of PRDM9, and possibly other long-array zinc-finger proteins, are unusually complex.
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Background
Genetic recombination is an essential feature of meiosis,
assuring an appropriate segregation of chromatids at the
first meiotic division, and generating an evolutionarily
important source of genetic variation by providing new
arrangements of alleles between genes linked on the same
chromosome. In many organisms, notably yeast [1], higher
plants [2], and mammals including humans and mice
[3-5], recombination is concentrated along chromosomes
at limited sites known as ‘hotspots’. Typically a kilobase in
extent, hotspots are surrounded by long stretches of DNA,
tens to hundreds of kilobases in extent, that are essentially
devoid of recombination in humans and mice.
Recently, several groups have shown that PR domain
member 9 (PRDM9), a zinc-finger (ZF) protein with his-
tone 3 lysine 4 (H3K4) methyltransferase activity, plays a
key role in determining the locations of hotspots in both
mice and humans [6-8]. It is presently proposed that
PRDM9 binds to appropriate DNA sequences in meiotic
chromatids, generates activated chromatin by virtue of its
H3K4 methyltransferase activity, and somehow guides the
generation of double-strand breaks (DSBs) at those sites
by the topoisomerase-like protein SPO11 [9]. Analyses of
individual human hotspots and a number of genome-wide
studies have implicated PRDM9 as the predominant regu-
lator of hotspot placement [6,7,10,11]. In mice, analyses of
genome-wide hotspots of DSB formation [12] make it
clear that PRDM9 determines the location of virtually all
hotspots, with the clear exception of the obligate crossover
at the pseudoautosomal region, at which recombination
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occurs equally well with different variants of PRDM9 pre-
sent, or indeed no variant at all. There is also evidence
that Prdm9 participates in transcriptional regulation
[13,14], which may be related to its involvement in hybrid
sterility [14].
Although PRDM9 plays a very important role in mam-
malian recombination, there is considerable uncertainty
as to how it physically determines hotspot locations and
then directs DSB formation there rather than at other tri-
methylated H3K4 (H3K4-me3) sites, of which there are
many. Meeting these challenges has repercussions both
for expanding the current understanding of recombina-
tion biology and for the insights this could provide in
understanding the functions of other regulatory proteins
with ZF arrays. More than 4% of human protein-coding
genes contain ZF arrays, and half of those arrays are
comparable in size with those present in PRDM9 [15-17].
The identification of PRDM9 as a regulator of human
recombination [7] relied on the finding that the DNA
sequence predicted to bind to the ZF array of the most
common human variant (variant A) matched a 13 bp
consensus sequence that characterizes 41% of human
hotspots [18], and the fact that although this sequence
is present in chimpanzee DNA, it does not characterize
chimpanzee hotspots. Baudat et al. [6] correlated human
hotspot activity with human allelic variation at PRDM9,
and predicted a mouse PRDM9 DNA binding sequence
found in a mouse hotspot. Parvanov et al. [8] identified
Prdm9 in mice by genetically mapping the gene control-
ling hotspot activity to a 181 Kb interval containing four
genes, three of which could be excluded as candidates.
Although PRDM9 reportedly binds to hotspot DNA
[6,19], there is still considerable confusion about the nat-
ure of the DNA sequences recognized by the ZF array of
PRDM9 and how this protein achieves its locational spe-
cificity. Many more copies of the human consensus
sequence are found in the genome at non-hotspot sites
than at the hotspots themselves [18], and Berg et al. [10]
showed that human hotspots possessing or not posses-
sing this consensus sequence are equally dependent on
PRDM9. In mice, the consensus sequence originally
predicted for the mouse PRDM9Cst variant [6] is more
commonly present in non-hotspot than in hotspot
regions, and the ZF prediction programs used in various
studies [20-22] also predict that the mouse Dom2 variant
of PRDM9 (PRDM9Dom2) should bind to hotspots that
genetic studies have shown are not activated by this
allele. Nevertheless, when tested experimentally, longer
oligonucleotides containing buried sequences matching
the predicted recognition motifs of two human PRDM9
alleles have been shown to bind PRDM9 protein
expressed in cell cultures [6,19].
To address the DNA binding problem experimentally,
we expressed the mouse Prdm9Cst allele (from the
CAST/EiJ strain; referred to below as CAST) and the
Prdm9Dom2 allele (from the C57BL/6J strain; referred to
below as B6) in Escherichia coli. and determined the
abilities of their respective protein products to bind DNA
sequences from three mouse hotspots (Hlx1, Esrrg1, and
Psmb9) known from genetic evidence to be activated by
Pdrm9Cst and one (Pbx1) known to be activated by
Prdm9Dom2. Binding between expressed PRDM9 and
DNA was tested both by the variant-specific ability of
PRDM9 to modify the electrophoretic mobility of target
DNA sequences and conversely, by the ability of DNA
binding-site sequences to physically sequester PRDM9.
Results
Histone H3K4 trimethylating activity
As an indication that the PRDM9 expressed in E. coli is
native protein, we first confirmed that it retains its his-
tone trimethylating activity. Both the induced
PRDM9Dom2 and the PRDM9Cst E. coli extracts showed
enhanced H3K4 trimethylating activity compared with
uninduced extracts, and induced empty vector (see
Additional file 1, Figure S1).
Fine mapping of Prdm9Dom2 and PRDM9Cst binding sites
The Hlx1 and Esrrg-1 hotspots, described in our pre-
vious work [8,23], require activation by the Prdm9Cst
allele, as does Psmb9 [6]. We concluded that the Pbx1
hotspot is dependent on the Prdm9Dom2 allele because it
was only active in crosses involving B6 and not active in
crosses lacking this genetic background (see Additional
file 2, Figure S2A).
Pbx1 had a single, PRDM9Dom2 allele-specific binding
site located at the left end of the interval tested (Figures
1A, B; see Additional file 2, Figure S2B). The shortest
Pbx1 oligo that showed binding to this allele, which has
12 contiguous ZFs, was 34 bp long (Figure 1C; see Addi-
tional file 2, Figure S2C). This is close to the 36 bp that is
predicted if all of the ZFs bind their expected 3 bp
sections. The binding site contained seven strong
matches to the binding site predicted for PRDM9Dom2 by
the linear Persikov-Singh algorithm [22] when aligned to
fingers 1 to 11 (Figure 1D), counting the 15 nucleotides
that are found at > 60% frequency at each position.
However, this was not statistically significant compared
with the 3.75 matches expected by chance (P = 0.057 by
a binomial distribution). The Pbx1 binding site is posi-
tioned 6 bp distal to the single-nucleotide polymorphism
(SNP) between the B6 and CAST strains within the
hotspot (see Additional file 2, Figure S2D). Surprisingly,
although this hotspot has a single binding site, the loca-
tions of the genetic crossovers within this hotspot depend
on the nature of the genetic cross used in its detection. In
the case of the B6xCAST and B6xPWD/PhJ interstrain
crosses, where the recombining mice are heterozygous
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across the entire genome, genetic crossovers were distrib-
uted on both sides of the binding site. However, in the
case of the B6xB6. CAST-1T congenic cross, where the
F1 mice are heterozygous only for the distal 100 Mb of
chromosome 1 and are homozygous across the rest of
the genome, genetic crossovers were located to one side
of the binding site (see Additional file 2, Figure S2A).
Hlx1 also possesses a single, variant-specific binding
site, this time located at the middle of the genetic interval
defining the hotspot (Figure 2A, B; see Additional file 3,
Figure S3A). The shortest Hlx1 oligo showing binding to
PRDM9Cst was 31 bp long (Figure 2C, left panel), close to
the 33 bp predicted if all 11 contiguous ZFs in this allele
bind their expected 3 bp. Both B6 and CAST sequences
showed nine matches to the binding site predicted for
PRDM9Cst by the linear Persikov-Singh algorithm, but at
different positions, and this was significant (P = 0.00034)
compared with the 3.5 matches expected by chance.
The B6 and CAST sequences at the Hlx1 binding site
differ at three positions (Figure 2D; see Additional file 3,
Figure S3B), of which two out of three affect binding
affinity and crossover rate in parallel at this hotspot.
Although both the B6 and CAST sequences bound
PRDM9Cst, binding by the B6 sequence was about 2.9
times stronger than that by the CAST sequence (Figure
2C, right panel). This corresponds with our previous
demonstration that initiation of meiotic recombination
at Hlx1 is about 2.5 times more frequent on the B6
chromosome than on the CAST chromosome [5]. A
recent estimate of Hlx1 by another method found about
a four-fold difference between the B6 and CAST
sequences using 41 bp oligonucleotides [19].
Figure 1 Mapping the PRDM9Dom2 binding site of Pbx1. (A) Scheme of Pbx1 hotspot with polymorphisms and amplicons for initial testing
of PRDM9Dom2 binding. The red line shows the position of the single binding site detected at this hotspot. (B) Pbx1 specifically binds to
PRDM9Dom2 but not PRDM9Cst. The compositions of the binding reactions are shown above each lane. Red arrow, shifted band; black arrow,
unbound fragment. (C) Detailed mapping of the Pbx1 binding site. The compositions of the binding reactions are shown above each lane. For
the sequences of the competitor oligos used for final mapping, see Additional file 11 (Additional experimental procedures). Red arrow, shifted
band; black arrow, unbound fragment. (D) The sequence of the 34 bp oligo representing the minimal binding site is aligned to the inferred
PRDM9Dom2 binding motif [6,21] and the zinc-finger array of PRDM9Dom2 (amino acids at positions -1, 3, and 6 relative to the a-helix of each
finger are shown). The strong matches of the binding site to the motif are in red.
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Esrrg-1 had a single, variant-specific binding site, also
located near the middle of the genetic interval identifying
this hotspot (Figure 3A; see Additional file 4, Figure
S4A). This binding site lacked any sequence differences
between B6 and CAST (see Additional file 4, Figure S4B).
The minimum length of the binding site for the Esrrg-1
hotspot was 33 bp (Figure 3C), and there were only four
strong matches to the binding site predicted for
PRDM9Cst (Figure 3G), which was not different from the
chance expectation (P = 0.31).
The Psmb9 hotspot has been identified and geneti-
cally characterized previously [24]. We tested only its
central region, where the PRDM9Cst binding reportedly
occurs [19] (Figure 3D), confirming this prediction.
Testing the reduced oligos, we found a 30 bp minimal
binding site showing allele specificity (Figure 3F). Its
best alignment to the predicted site had eight strong
matches (Figure 3G), which is likely to be significant
(P = 0.00098).
Comparison of PRDM9Cst binding sites
The lengths of the three binding sites (30 to 33 bp) sug-
gests that binding involves all of the Zn fingers in the
array, with the possible exception of either the first or
Figure 2 Defining the PRDM9Cst binding site of Hlx1. (A) Scheme of Hlx1 hotspot with polymorphisms between the C57BL/6J (B6) and the
CAST/EiJ (CAST) mouse strains (from Paigen et al. [5]) and amplicons for initial testing of PRDM9Cst binding. The positions of single-nucleotide
polymorphisms (SNPs) were taken from the National Center for Biotechnology Information (NCBI) build 37. The red line represents the only
fragment showing binding at Hlx1. (B) Hlx1 specifically binds to PRDM9Cst but not PRDM9Dom2. The compositions of the binding reactions are
shown above each lane. Red arrow, shifted band; black arrow, unbound fragment. (C) Detailed mapping of the Hlx1 binding site. The
compositions of the binding reactions are shown above each lane. For the sequences of the competitor oligos used for final mapping, see
Additional file 11 (Additional experimental procedures). (Left panel) Definition of the minimal binding site; (right panel) Strength of binding of
PRDM9Cst to B6 and CAST sequences of the Hlx1 binding site. Red arrow, shifted band; black arrow, unbound fragment. (D) Sequences of the
Hlx1 minimal binding sites in B6 and CAST strains aligned to the inferred PRDM9Cst binding motif. Sequence differences are underlined. The
strong matches of the binding sites to the motif are in red. (E) Hlx1 competes with the other PRDM9Cst-dependent binding sites. The
compositions of the binding reactions are shown above each lane. Red arrow, shifted band; black arrow, unbound fragment.
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the last finger, noting that the first finger has an ECH2
configuration rather than C2H2.
There is very little similarity between the sequences of
the three PRDM9Cst binding sites. Any pairwise matches
in sequence for the three sites were distributed over the
entire length of the binding sites. The best alignment of
the three minimal binding sites for the PRDM9Cst ZF
array identified only four conserved positions (P = 0.052)
(see Additional file 5, Figure S5, red); two would have
been expected by chance. These triple matches are
located at positions predicted to bind the second, fourth,
sixth, and eighth fingers of PRDM9Cst. Pairwise compari-
sons identified 15 matches between Hlx1 and Esrrg-1
(see Additional file 5, Figure S5, red and green), 12
matches between Hlx1 and Psmb9 (see Additional file 5,
Figure S5, red and yellow), and only 6 matches between
Psmb9 and Esrrg-1 (see Additional file 5, Figure S5, red
and cyan). We examined this level of similarity using two
statistical methods. Using the c2 test, the probability that
the number of nucleotide matches between the three
sites (scored as 0, 2, or 3 matches at each position)
exceeds chance was 0.048 (barely significant), and this
Figure 3 Defining the PRDM9Cst binding sites of Esrrg-1 and Psmb9. (A) Scheme of Esrrg-1 hotspot with polymorphisms between C57BL/6J
(B6) and CAST/EiJ (CAST) and amplicons for initial testing of PRDM9Cst binding. The red line represents the only fragment showing binding at
this hotspot. (B) Esrrg-1 specifically binds to PRDM9Cst but not PRDM9Dom2 and competes with the other PRDM9Cst-dependent binding sites. The
compositions of the binding reactions are shown above each lane. Red arrow, shifted band; black arrow, unbound fragment. (C) Detailed
mapping of the Esrrg-1 binding site. The compositions of the binding reactions are shown above each lane. For the sequences of the
competitor oligos used for final mapping, see Additional file 11 (Additional experimental procedures). Red arrow, shifted band; black arrow,
unbound fragment. (D) Scheme of Psmb9 hotspot with polymorphisms between B6 and CAST, and amplicons for initial testing of PRDM9Cst
binding. The approximate position of the Psmb9 binding site was reported previously [19], and therefore only three amplicons surrounding it
were tested. Only the middle fragment showed binding to PRDM9Cst. (E) Psmb9 specifically binds to PRDM9Cst but not PRDM9Dom2 and
competes with the other PRDM9Cst-dependent binding sites. The compositions of the binding reactions are shown above each lane. Red arrow,
shifted band; black arrow, unbound fragment. (F) Detailed mapping of the Psmb9 binding site. The compositions of the binding reactions are
shown above each lane. For the sequences of the competitor oligos used for final mapping, see Additional file 11 (Additional experimental
procedures). Red arrow, shifted band; black arrow, unbound fragment. (G) Sequences of the Esrrg-1 and Psmb9 minimal binding sites aligned
with the inferred PRDM9Cst binding motif. The strong matches of the binding sites to the motif are in red.
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significance entirely disappeared when we considered only
the 17 positions where the mutation analysis (see below)
indicated the strongest evidence for nucleotide specificity.
Additionally, using the binomial distribution for pairwise
comparisons, we found some support for similarity
between Hlx1 and Esrrg-1 (P = 0.003) and between Hlx1
and Psmb9 (P = 0.048), but not between Psmb9 and
Esrrg-1 (P = 0.75). Given this marginal sequence similarity
between the three PRDM9Cst binding sites, we confirmed
by testing their ability to compete with each other for
binding that they do in fact bind to the same molecular
entity. The sites do compete with each other, and the data
suggest that Hlx1 and Psmb9 both bind more strongly
than Esrrg-1 (Figure 2E; Figure 3B, E). There was also no
consistency in the binding specificity of the same ZF
located at different positions in the array. The amino acids
at positions -1, 2, 3, and 6 in each finger are thought to
make contact with the DNA helix and determine binding
specificity [21,22,25]. These amino acids are identical
(ASNQ), as are all the rest of the amino acids in fingers 2,
5, 7, and 9 of the PRDM9Cst Zn finger array, and all 11
fingers in this array contain serine at the -2 position,
which is also thought to contribute to specificity. Never-
theless, fpr the three PRDM9Cst binding sites, there is no
consistency in the four triplets that these four fingers bind
(see Additional file 5, Figure S5). A similar result was seen
for the nucleotides binding the pairs of identical fingers in
the PRDM9Dom2 variant at the Pbx1 hotspot.
In vivo H3K4 trimethylation sites
The locations of the DNA binding sites for all hotspots
were within the regions representing the peak locations
of meiotic histone H3K4-me3 marks that result from
PRDM9 binding; these were measured in mouse testes
by chromatin immunoprecipitation (ChIP) using an
antibody against H3K4-me3 (Figure 4). The same pat-
tern has been previously reported for Psmb9 [19,26]. It
should be noted that the histone modification occurs
over appreciable distances, a kilobase or more from the
actual binding site itself, indicating that H3K4-trimethy-
lation at hotspots involves nucleosomes beyond those
immediately adjacent to the binding site.
Computer predictions
The algorithms developed by Persikov and Singh [22]
are commonly used to predict ZF DNA binding
sequences. These include both a linear prediction pro-
gram based on an elemental identity of trinucleotide
binding sequences for each finger, and a polynomial
form of the program that takes nucleotide interactions
into account. In every case, when both programs were
tested against 200 bp sequences surrounding the four
identified binding sites, the programs identified multiple
binding sites within the 200 bp sequence. In only two of
the eight tests was the actual binding site the top scor-
ing site; in two cases, the program failed to identify the
binding site at all, and the quality of prediction declined
noticeably when tested against longer DNA sequences.
The performance of the linear and polynomial predic-
tion programs differed for each hotspot. Only the poly-
nomial program correctly identified the Hlx1 binding
site, whereas only the linear program identified Pbx1.
Both programs identified Esrrg-1 and Psmb9 (see Addi-
tional file 6, Table S1).
As an alternative, we used a position-weighted matrix
[27] derived from the detailed binding requirements of
the Hlx1 hotspot (see Additional file 7, Table S2) to
scan for DNA binding sites that coincide with geneti-
cally determined hotspots on mouse chromosomes 1
and 11 [5,28]. Unfortunately, we failed to find a DNA
binding motif common to genetically identified hotspots
on these chromosomes.
Mutational characterization of the Hlx1 binding site
Given the diversity of the PRDM9Cst binding sites, we
chose the Hlx1 DNA sequence to further characterize
the binding specificities of PRDM9 and to determine the
nucleotide specificity of each position in the binding site.
Because it was not possible to test all 1019 combinations
of base pairs in a 31 bp oligo, we used a competition
assay to determine how binding was affected when each
base pair was replaced in turn by its three possible alter-
natives. For this, we first determined the kinetics of repla-
cement of an already bound double-stranded oligo by a
competitor (see Additional file 8, Figure S6A). The repla-
cement rate was very slow, indicating very tight binding;
reduction of the signal by unlabeled competitor was
apparent only after 4 hours of incubation. This made
possible a competition assay in which unlabeled mutated
oligos were pre-incubated with expressed PRDM9Cst for
1 hour, then one-twentieth the number of molecules of
labeled oligo of the original sequence were added, and
the mixture was incubated for an additional 4 hours. At
the end of the incubation, the extent of binding of the
labeled oligo was tested by using the electrophoretic
mobility assay (see Additional file 8, Figure S6B). Because
the presence of a biotin tag at the end of the minimum
binding sequence diminishes binding affinity, the labeled
oligo was 75 bp long, with the binding site located in the
middle, while the competing oligos were 36 bp long,
including two additional base pairs at the 5’ end and
three additional base pairs at the 3’ end relative to the
minimal 31 bp binding site. In this assay, the ability of a
mutated oligo to reduce subsequent binding by labeled
oligo provided a measure of its ability to bind PRDM9;
appearance of a strong signal band indicated that the
unlabeled mutated oligo failed to bind PRDM9, a weaker
signal indicated lower binding strength, and lack of any
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signal indicated very strong binding. The results of these
tests are presented (Figure 5A; see Additional file 8,
Figure S6C), and summarized in graphical form (Figure
5B), where we assumed the 5’-3’ orientation of the DNA
to be relative to the N-C orientation of the ZF array,
based on its much better fit to the computer-predicted
binding sequence, rather than the reverse.
The 31 positions of the Hlx1 site varied greatly in their
specificity. As a simple measure of the degree of specifi-
city, we calculated the standard deviation (SD) of the
measured binding affinities at each position (see
Additional file 9, Table S3). Using this indicator of speci-
ficity, the positions fell into three groups: 13 of low speci-
ficity (SD = 0.03 to 0.12), 10 of moderate specificity (SD
= 0.16 to 0.36), and 8 with the highest specificity (SD =
0.45 to 0.52), located at fingers 4, 5, and 6 near the center
of the binding site. The weakest specificity was at the C-
terminal end, fingers 9 to 11, corresponding to positions
25 to 33 of the binding site. Given that these fingers are
nevertheless required for binding, it is possible that they
function in a non-sequence-specific manner, for example
by stabilizing the contact between PRDM9 and DNA
Figure 4 H3K4-me3 marks are enriched near the binding sites of the hotspot tested. The peak of H3K4-me3 at hotspots is centered near
the PRDM9 binding site. Chromatin was prepared using spermatocytes from mice 12 days post-partum and subjected to chromatin
immunoprecipitation (ChIP) with antibody directed to H3K4-me3 or normal rabbit IgG. Quantitative PCR was performed for 8 to 9 amplicons
distributed across about 10 kb surrounding the hotspot on immunoprecipitated chromatin and an equal amount of MNase-treated, undiluted
input DNA to calculate the fraction of chromatin bound at each amplicon. Blue line, B6 × CAST F1; green line, B6; red line, rabbit IgG (negative
control). An identical distribution of H3K4-me3 marks for Psmb9 was shown previously by Grey et al. [19].
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through charge interactions involving the phosphate
backbone. In this regard, it is interesting that these
fingers seem to be less subject to evolutionary selection;
the last two fingers are invariant between mouse alleles,
and the next has only a single amino acid substitution, N
for V. Replacement of nucleotides 1 to 2 and 34 to 36,
adjacent to the shortest 31 bp sequence (see Additional
file 8, Figure S6C), also affected binding affinity, lending
further support to the possibility of more complex inter-
actions between DNA and ZFs.
Magnesium inhibition
Our data suggesting that binding might involve mechan-
isms other than interaction with nucleotides in the major
groove of DNA, as presently assumed [33], prompted us
to test the effect of Mg2+ ions, which are well known to
interact with polyphosphates. We found that binding is
strongly inhibited at concentrations above 1 mmol/l and
nearly completely inhibited by 10 mmol/l (see Additional
file 10, Figure S7). This inhibition was essentially identi-
cal for both the PRDM9Dom2 and PRDM9Cst variants at
all four hotspots tested. The possible involvement of the
phosphate backbone of DNA in binding to PRDM9
seems to be a particular characteristic of PRDM9 rather
than a general characteristic of ZF proteins, as it is nota-
bly different from the effects of Mg2+ on DNA binding by
the ZF proteins WT1 and EGR1 [29]’ for those proteins,
millimolar concentrations of Mg2+ activated binding, and
higher concentrations had little inhibitory effect [29].
Discussion
Taken together, our results confirm that the binding seen
with PRDM9 expressed in E. coli correctly recapitulates
the biological specificities of PRDM9, including its allelic
specificity, the haplotype specificity of its target, and the
location of the binding sites near the peaks of hotspot
Figure 5 Nucleotide substitution analysis of Hlx1-B6 binding to PRDM9Cst. (A) Competition assay for testing the binding of PRDM9Cst to
mutated Hlx1 binding sites. Substitutions of nucleotides 4 to 6; labeled oligos are indicated by asterisk. The compositions of reaction mixtures in
the first three lanes are shown above each lane. Lanes 4 to 12 show the competition test with mutated oligos. The position and the nature of
each mutation in the oligo are shown. The composition of the reaction mixtures in lanes 4 to 12 is mutated oligo + PRDM9Cst + oligo* (see
Materials and methods). The fraction of the shifted band is indicated below each lane. Red arrow, shifted band; black arrow, unbound fragment.
(B) Graphic representation of the binding changes at each position produced by the nucleotide substitution analysis. (C) ZF domain of
PRDM9Cst. The letters in the boxes show the amino acids at positions -1, 3, and 6 relative to the a-helix of each finger.
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H3K4 trimethylation detected in vivo. Moreover, the cor-
relation between the binding affinities of different Hlx1
haplotypes and their genetically measured rates of cross-
over also suggest that the strength of the physical binding
of PRDM9 to hotspot sequences may determine the effi-
ciency of recombination initiation. There was little
sequence similarity between the several binding sites for
the same PRDM9 variant, and the binding specificities of
individual fingers appeared to be context-dependent.
Mutational analysis of the Hlx1 binding site indicates
considerable variation between the ZFs in their contribu-
tion to overall binding affinity and the probable involve-
ment of the DNA phosphate backbone.
These findings have relevance to the general role of
ZF arrays as a DNA-recognition motif in biology, given
that ZF proteins are the most common DNA regulatory
protein in vertebrate genomes, comprising over 4% of
all protein-coding genes in humans, and that half of
these contain 10 or more fingers. They are almost as
common in invertebrates, in which they were first
described [17]. The issues surrounding the DNA binding
specificities of ZFs are both biological and chemical.
Biologically, we want to derive a consensus binding
sequence whose parameters predict the location and
relative binding affinity of genomic binding sites, and
then describe how these affinities relate to biological
outcomes. Chemically, we want to understand how the
specificity of binding sequences is determined by the
atomic and molecular interactions between protein and
DNA.
PRDM9 provides a particularly useful system for
addressing these issues. It is highly variable, with multi-
ple variants available both within and between species.
It is a multiply fingered protein, providing the opportu-
nity to examine interactions between repeat fingers in
the same protein. In addition, there are many thousands
of binding sites in genomes, providing a considerable
source of experimental material. To our knowledge, the
data we now report provide the first detailed definition
of the DNA binding specificities of a ZF protein with a
long (> 10) array of contiguous fingers. What has
emerged is a picture of considerable complexity, one
that raises as many or more questions than it answers.
Binding-site positions
It was somewhat surprising to find that PRDM9 binding
sites are not uniformly positioned in relation to hotspot
centers. One possible explanation for this asymmetry
could be the presence of crossover refractory zones cre-
ated by the nature of adjoining DNA sequences that cre-
ate directionality in the spreading of the Holliday
junctions away from initiation sites [30]. However, our
genetic data point to a more likely alternative. The
sequence of the Pbx1 hotspot is identical in B6xCAST
and B6xB6. CAST-1T crosses, but the crossovers in the
former cross are resolved on both sides of the binding
site, whereas the eight-fold larger number of crossovers
in the latter cross are almost exclusively on one side of
the binding site. In the absence of possible cis effects,
this suggests a role for additional trans-acting factors in
affecting the directional processing of recombination
intermediates, with attendant consequences for overall
crossover rates at this hotspot.
Extent of ZF usage
A notable feature of PRDM9 is the required use of all,
or nearly all, of its contiguous fingers for binding DNA,
as evidenced by the requirement for 35 to 37 bp for
PRDM9Dom2, which has 12 fingers, and 30 to 33 bp+ for
any binding activity by PRDM9Cst, which has 11 fingers
(the plus indicating that binding is further enhanced at
the Hlx1 hotspot by an additional 3 bp, one of which
shows considerable nucleotide specificity). This long
binding array presents a topological issue, as it seems
that at least five to six fingers make base pair-specific
contacts with DNA. Moreover, detailed analysis of the
Hlx1 binding site revealed that multiple nucleotide posi-
tions between positions 5 and 21 show appreciable
nucleotide specificity, without any gaps longer than 2
bp. If, as in the case of other ZF proteins, these specific
contacts form in the major groove of DNA, it suggests
that the ZF domain of PRDM9 can bind continuously
along the major groove for more than one turn of the
DNA double helix. In the context of intact cellular
DNA, this would require a snake-like winding of the
DNA around its target, which is in marked contrast to
the accepted rule that ZF proteins do not use more than
three contiguous fingers to bind DNA [22], and thus
requires further explication. Given the further observa-
tion that binding is inhibited by magnesium, which
complexes with polyphosphates, the requirement for
additional fingers with low sequence specificity may
indicate the importance of non-specific charge interac-
tions between negatively charged phosphate groups and
the positively charged Zn2+ and histidine residues.
Binding-site relatedness
The three DNA binding sites identified for the
PRDM9Cst variant bear little ostensible resemblance to
each other, with little identity between the nucleotide
positions along the entire length of these sequences.
However, a more subtle relationship between the three
sequences can be detected when they are compared
with the mutation-analysis data for Hlx1. This suggests
that both the strongest binding within an Hlx1 site and
most of the sequence matches between the three bind-
ing sites occur over the nucleotides binding to the first
six fingers of the PRDM9Cst ZF array. The binding rules
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are obviously complex, and this complexity was empha-
sized when we examined the Hlx1 hotspot in detail; the
mutation analysis showed variable stringency along its
length for base-pair identities. At every position, two,
three, and often all four bases could serve, albeit not
always equally well.
Context dependence of ZF specificity
In addition to the weak similarity between binding
sequences, there was also a strong context dependence
of DNA binding, with the binding properties of a finger
being dependent on its location in the array. Although
the second, fifth, seventh, and ninth ZFs of PRDM9Cst
have identical amino acid sequences, they did not bind
related trinucleotide sequences either within or between
hotspots (see Additional file 5, Figure S5).
Evolutionary context
Previous three-dimensional studies of ZF DNA interac-
tions suggest a model in which four amino acids in each
finger (positions -1, +2, +3, and +6) bind four consecutive
base pairs in DNA. The last of the four bases shares its
binding with the next finger, giving a repeating pattern of
3 bp per finger (plus 1 bp for the total possible length of
the binding site) [25]. Computer analyses of multiple 3D
structures indicate that all four amino acids are equally
important [22]; however, the evolutionary data suggest
otherwise for PRDM9. The amino acid composition of its
ZFs undergoes rapid evolutionary selection to generate
new hotspots as existing hotspots undergo continual loss
by mutation [31]. Notably, position +2 is essentially
invariant in the face of extraordinarily high replacement
rates at positions -1, +3, and +6 [8,10,32,33], suggesting
that, at least for PRDM9, this amino acid plays a lesser
role in determining DNA binding specificity.
Conclusions
Our findings introduce considerable complexity into
efforts to understand DNA binding by long-array ZF pro-
teins such as PRDM9. The binding sites for the
PRDM9Cst variant are only very subtly related; identical
ZFs show little constancy in the trinucleotides they bind,
and a position weight matrix approach [27] failed in a
search for a DNA binding motif common to genetically
identified hotspots on mouse chromosomes 1 and 11
[5,28]. Perhaps most surprising is the finding that binding
requires DNA sequences involving more than one helical
turn, even though the terminal nucleotide positions show
little sequence specificity. To our knowledge, PRDM9 is
the first long-array ZF protein to have its DNA binding
specificity at separate binding sites compared in detail. At
issue now are the biological question of how to solve the
binding rules for PRDM9 and the chemical question of
whether the binding complexities of PRDM9 are shared
by the hundreds of other long-array ZF proteins that
carry out a great diversity of biological functions.
Materials and methods
Cloning and expression of mouse Prdm9
Full-length Prdm9 was amplified from cDNA prepared
from the testes of CAST/EiJ (CAST) and C57BL/6J
(B6) mouse strains using primers Prdm9F-HisB and
Prdm9R-HisB (for sequences of primers used for clon-
ing and sequencing, see Additional file 11) and cloned
into pBAD/HisB (Invitrogen Corp., Carlsbad, CA,
USA) using XhoI and HindIII restriction sites added
to the 5 ’-ends of the primers. The identity of the
cloned products was confirmed by sequencing (see
Additional file 12). The plasmids were transformed
into TOP10 E. coli cells, allowing arabinose induction
of protein synthesis. For production of PRDM9 pro-
tein, the cells were grown overnight in Luria broth
and then incubated an additional 4 hours with the
addition of 0.02% arabinose. Total cell lysate was pre-
pared in native binding buffer (50 mmol/l sodium
phosphate pH 8 and 500 mmol/l NaCl) in accordance
with the manufacturer’s specifications, and stored at
-80°C until use, when it was heated at 50°C for 15
minutes to inactivate bacterial DNAses. The produc-
tion of full-length protein was confirmed by western
blotting using an antibody to the N-terminal his tag.
Crude bacterial lysates used in the in vitro binding
assays contained 15 to 30 μg/ml expressed PRDM9 as
estimated by ELISA.
Histone methylation assay
Crude bacterial extract containing induced/non-induced
PRDM9 variants or empty pBAD/HisB vector were
heated for 15 minutes at 50°C, then used for a histone
methyltransferase assay. The reaction mixture contained
20 μl 2× HMT buffer (50 mmol/l Tris-HCl pH 8 and
20% glycerol), 2 μl S-adenosinmethionine (100 μg/ul;
Sigma-Aldrich, St Louis, MO, USA), 10 μl bacterial
extract, 0.2 μl histone substrate (0.5 μg/μl recombinant
H3K4-me2; Active Motif, Carlsbad, CA, USA), and 7.8
μl water. The reaction was kept at 34°C for 30 minutes.
Several commercially available antibodies were used to
detect specific H3K4me3 signals. All tested antibodies
showed cross-reactivity with H3K4me2. Therefore, we
estimated the level of H3K4 trimethylation by induced
PRDM9 relative to controls with induced empty vector.
The results presented here were obtained using the anti-
body that showed the most consistent discrimination
between H3K4me2 and H3K4me3 signals (recombinant
H3K4-me2; Active Motif).
Histone methyltransferase activity was measured by
dot blotting. The reaction mixtures were blotted onto
nitrocellulose membrane and the trimethylated H3K4
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was detected with anti-H3K4me3 antibodies (Active
Motif). The chemiluminiscent signal was visualized
(Lumiglo Kit; Cell Signalling Technology, Danvers, MA,
USA) and scanned with an image scanner (ImageQuant.
LAS-4000; GE Healthcare, Princeton, NJ, USA) The
fraction of the specific H3K4me3 signal was calculated
as
FH3K4me3 = (Sind − Sun)
/
(SH3K4me3 − SH3K4me2),
where FH3K4me3 is the fraction of the specific signal,
Sind and Sun are the signals of induced and uninduced
extracts, and SH3K4me3 and SH3K4me2 are the signals of
commercial H3K4me3 and H3K4me2, respectively.
Electrophoretic mobility shift assay
Using an electrophoretic mobility shift assay (EMSA)
(LightShift Chemiluminescent EMSA Kit; Pierce Bio-
technology ThermoScientific, Rockford, IL, USA), a bio-
tin-labeled test oligo and PRDM9 were allowed to bind
in a mixture containing 10 mmol/l Tris (pH 7.5), 50
mmol/l KCl, 1 mmol/l dithiothreitol, 50 ng/μl poly(dI/
dC), 0.05% NP-40, 0.5 pmol/l of labeled double-stranded
oligo, and 3 μl of bacterial extract in a total volume of
20 μl. When necessary, 10 pmol/l of cold competitor or
non-competitor was added. The reaction mixture was
incubated for 40 minutes and separated on 5% PAA gel
in 0.5× Tris-borate-EDTA (TBE) buffer, which was pre-
electrophoresed for 30 minutes. After electrophoresis,
the separated products were transferred onto nylon
membrane by wet transfer in 0.5× TBE at 380 mA for 1
hour. The membrane was cross-linked by UV light at
120 mJ/cm2 (UV Stratalinker 2400; Agilent Technolo-
gies, Santa Clara, CA, USA). Biotin-labeled products
were detected by the chemiluminescence signal pro-
duced by the binding to streptavidin-peroxidase conju-
gate in accordance with the manufacturer’s specification,
and the chemiluminesce signal was recorded (G:BOX
system; Syngene, Frederick, MD, USA).
Single-stranded oligos were biotin-labeled at the 3’-
end *Biotin 3’ End DNA Labeling Kit; Pierce Biotechnol-
ogy ThermoScientific) in accordance with the manufac-
turer’s specifications. Complementary oligos were then
mixed, denatured at 95°C for 2 minutes, and annealed
by cooling down to room temperature in a water bath.
When a PCR product was labeled, the two strands were
separated by heating at 95°C for 5 minutes. The tube
was immediately transferred to ice, and then the pro-
duct was labeled and re-annealed as above.
The bands were quantified using Gene Tools software
(Syngene, Frederick, MD USA), using the ‘Manual
bands’ and ‘Absorption’ settings. Equal-sized rectangles
were drawn around each shifted and unshifted band
present, and the absorption density was scored
automatically by the software. The proportion of shifted
band was calculated as S/(S+U), where S is the density
of the shifted band and U is the density of the unshifted
band.
The DNA binding sites of hotspots were localized by
testing whether the electrophoretic mobility of biotin
end-labeled DNA sequences was altered after binding to
the PRDM9Cst and PRDM9Dom2 proteins expressed in E.
coli. All binding experiments were performed using
crude E. coli extracts, because every attempt to purify
PRDM9 resulted in insolubility and loss of activity. The
specificity of binding was confirmed by appropriate con-
trols, including induced cells that had been transformed
with empty vector, and the host cells alone. Addition-
ally, the variant-specific binding of PRDM9 to hotspot
sequences was confirmed by isolation of protein-biotiny-
lated DNA complexes onto streptavidin beads and
detection of PRDM9 by western blotting with antibodies
against its C-terminal end (see Additional file 13, Figure
S8).
To localize binding sites, a tiling approach was used,
in which PCR-amplified fragments of 200 to 400 bp,
overlapping by 50 bp, were tested for their ability to
bind PRDM9 variants (Figures 1A, 2A, 3A, D; also see
Additional file 2, Figure S2B; Additional file 2, Figure
S3A; Additional file 2, Figure S4A). Positive fragments
were then reduced to less than 100 bp using the same
strategy. Because biotin labeling close to the end of a
binding-site sequence influences binding, the limiting
sequence for each binding site was then determined by
comparing the binding ability of progressively shorter,
unlabeled oligos against the binding ability of longer,
labeled oligos.
Mutational analysis
For the competition assays testing how single-nucleotide
substitutions affect DNA-PRDM9 binding, bacterial
extract was incubated with 10 pmol/l of unlabeled dou-
ble-stranded oligo for 1 hour (all other components
except labeled oligo were as given above), then 0.5
pmol/l labeled oligo was added, and the extract was
incubated for an additional 4 hours (see Additional file
8, Figure S6A). Under these conditions, appearance of a
strong, shifted, labeled DNA band indicates that the
mutated sequence shows weak or no binding, whereas a
weakly shifted band indicates strong binding by the
mutated oligo (see Additional file 5, Figure S5B). The
separation and detection conditions were the same as
described above. The strength of binding of each
mutated oligo to PRDM9Cst was then determined by
comparing its ability to replace previously bound,
labeled, Hlx1 oligo with the abilities of the unlabeled
oligo and an unlabeled oligo with a randomly scrambled
Hlx1 sequence. Competition was calculated as:
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Bmut = (Sun − Smut)
/
(Sscr − Sun),
where Bmut is the relative change in binding strength
of the mutated oligo, and Sun, Smut, and Sscr are the pro-
portions of shifted bands of the unmutated, mutated,
and scrambled oligos, respectively.
Streptavidin pull-down and western blotting
Protein-biotinylated DNA complexes were isolated on
streptavidin beads. PRDM9 variants were expressed in
E. coli and bound to biotinylated oligos representing bind-
ing sites, as described above for the EMSA experiments.
The complexes were then isolated on T1 streptavidin-
coated beads (Dynabeads; Invitrogen Dynal, Oslo, Norway)
and washed three times with EMSA binding buffer, then
the bound proteins were released from the beads by add-
ing 0.1% SDS. The proteins were separated on 4 to 20%
SDS gels and transferred onto polyvinylidene difluoride
(PVDF) membrane, and the specificity of PRDM9 binding
was detected on western blots using mouse antibodies
against the C-terminal part of PRDM9.
Chromatin immunoprecipitation for H3K4-me3
Crude isolation of spermatocytes from B6 and B6xCAST
F1 juvenile mice was performed as reported previously
[34] with minor modifications.
Spermatocytes were isolated from testes of 12-dpp
juvenile mice. Cross-linking of spermatocytes was per-
formed by addition of formaldehyde to a final concen-
tration of 1% and incubation at room temperature for
10 minutes with constant rotation. Cross-linking was
stopped by dropwise addition of glycine to a final con-
centration of 125 mmol/l, followed by incubation with
rotation for 5 minutes at room temperature. Cells were
washed twice, separated by centrifugation at 2000 g for
5 minutes at 4°C, and resuspended in 1 ml PBS. After
the final wash, hypotonic lysis buffer (10 mmol/l Tris-
HCL pH 8.0, 1 mmol/l KCl, 1.5 mmol/l MgCl2) was
added at a concentration of 5 × 106 cells/ml supplemen-
ted with 1 mmol/l phenylmethanesulfonylfluoride
(PMSF) and 1× protease inhibitor cocktail (PIC; Sigma-
Aldrich) and incubated for 30 minutes at 4°C with rota-
tion to shear the cellular membrane. Nuclei were pel-
leted by centrifugation at 10,000 g for 10 minutes and
resuspended in MNase buffer (50 mmol/l Tris, 1 mmol/
l CaCl, 4 mmol/l MgCl, 4% NP-40) at 26 μl/106 cells,
supplemented with 1 mmol/l PMSF and 1× PIC. Chro-
matin was fragmented and solubilized by addition of
MNase (USB, Cleveland, OH, USA) at 15 U per 5 × 106
cells, followed by incubation for 2 minutes at 37°C.
Nuclease activity was stopped by addition of EDTA to a
final concentration of 10 mmol/l and incubation at 4°C
for 5 minutes. Soluble chromatin was clarified by
centrifugation at 4°C for 10 minutes at top speed, then
the supernatant was transferred to a clean tube and the
centrifugation repeated. H3K4me3 antibody (Millipore
Corp., Billerica, MA, USA) was prebound to 20 μl pro-
tein-G beads (Dynabeads; Invitrogen Corp.) following
the manufacturer’s protocol. Antibody-bound beads
were washed twice with 100 μl of immunoprecipitation
(IP) buffer (RIPA 50 mmol/l Tris pH 8.0, 150 mmol/l
NaCl, 1.0% NP-40, 0.5% Na deoxycholate, 0.1% SDS
supplemented with 50 mg/ml BSA, and 0.5 mg/ml sal-
mon-sperm DNA) and resuspended in a final volume of
75 μl IP buffer with PMSF and 1× PIC. Undiluted chro-
matin (25 μl; around 106 cell equivalents) was added to
the beads, and incubated with rotation at 4°C for
2 hours. The chromatin-bound beads were washed three
times with 100 μl IP buffer and then twice with 100 μl
TE buffer pH 8.0 before elution with 125 μl elution buf-
fer (1% SDS, 20 mmol/l Tris-HCL pH 8.0, 200 mmol/l
NaCl, 5 mmol/l EDTA) supplemented with 50 μg/ml
Proteinase K (Sigma-Aldrich). Elution was carried out
by incubation at 68°C for 2 hours with vigorous shaking
at top speed in a thermal mixer (Thermomixer; Eppen-
dorf, Westbury, NY, USA) to reverse cross-links and
digest all proteins. An equal aliquot (25 μl of ‘input’
chromatin was diluted to a final volume of 125 μl with
elution buffer and handled in parallel. DNA was recov-
ered from the beads using magnetic separation, placed
into a clean tube, and then purified using commercially
available methods following the manufacturer’s protocol
for PCR clean up (Qiagen Inc., Valencia, CA, USA).
Purified DNA was eluted in a total volume of 200 μl
10 mmol/l Tris pH 8.0.
Primers were designed using OligoPerfect™ primer
design software (Life Technologies, Corp., Carlsbad, CA,
USA) using the following parameters, 40 to 60% GC, 57
to 63°C Tm, with a product size of 8 to 120 bp. Each
qPCR reaction was performed in triplicate 20-μl reac-
tions using a commercial kit (Quantifast SYBR Green
PCR Kit; Qiagen Inc.) and following the manufacturer’s
protocol,, then run on a real-time PCR system) (Master-
Cycler® ep realplex; Eppendorf) for 40 cycles, followed
by a melting-curve analysis. Ct values were calculated
using an automated threshold and averaged for triplicate
experiments. If a PCR reaction failed to amplify in the
IgG control, the Ct value for that reaction was arbitra-
rily set to 35 cycles, typically around 12 cycles less than
the input sample (or less than 0.024%). Reactions for
both the input and ChIP sample were seeded with 2 μl
of DNA. The percentage of chromatin-bound (fraction
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Bioinformatic search for a DNA binding motif
A position weight matrix (PWM) was created (Table S2)
based on the mutational analysis of the Hlx1 binding
site, and a matrix matching algorithm from the software
package Motif Occurrence Detection Suite [27] was
used. The weights obtained for the matrix were opti-
mized by maximizing the score for the detection of the
Hlx1 binding site within a scan against the entire Hlx1
hotspot region. Subsequently, the PWM was used in a
scan against all hotspots less than 10 Kb in size located
on chromosome 1, along with control regions adjacently
positioned before and after each hotspot; each control
region was sized equivalently to its corresponding hot-
spot. To minimize the effects of multiple testing, only
matches with P-values below 10-5 were considered.
Additional material
Additional file 1: Figure S1. Escherichia coli-expressed PRDM9
protein variants retain their H3K4 trimethylation activity. The
Additional material contains maps of all hotspots studied in this paper,
their sequences, additional figures and tables highlighting specific points
in the paper, and the sequences of the oligos used for mapping.
Additional file 2: Figure S2. The PRDM9Dom2 binding site of Pbx1.
The Additional material contains maps of all hotspots studied in this
paper, their sequences, additional figures and tables highlighting specific
points in the paper, and the sequences of the oligos used for mapping.
Additional file 3: Figure S3. The PRDM9Cst binding site of Hlx1. The
Additional material contains maps of all hotspots studied in this paper,
their sequences, additional figures and tables highlighting specific points
in the paper, and the sequences of the oligos used for mapping.
Additional file 4: Figure S4. The PRDM9Cst binding site of Esrrg-1.
The Additional material contains maps of all hotspots studied in this
paper, their sequences, additional figures and tables highlighting specific
points in the paper, and the sequences of the oligos used for mapping.
Additional file 5: Figure S5. Alignment of the three PRDM9Cst
binding sites. The Additional material contains maps of all hotspots
studied in this paper, their sequences, additional figures and tables
highlighting specific points in the paper, and the sequences of the
oligos used for mapping.
Additional file 6: Table S1. Persikov algorithm predictions for 200
bp regions surrounding binding sites. The Additional material
contains maps of all hotspots studied in this paper, their sequences,
additional figures and tables highlighting specific points in the paper,
and the sequences of the oligos used for mapping.
Additional file 7: Table S2. Position-weighted matrix based on the
results of the electrophoretic mobility shift assay (EMSA). The
Additional material contains maps of all hotspots studied in this paper,
their sequences, additional figures and tables highlighting specific points
in the paper, and the sequences of the oligos used for mapping.
Additional file 8: Figure S6. Nucleotide substitution analysis of Hlx1.
The Additional material contains maps of all hotspots studied in this
paper, their sequences, additional figures and tables highlighting specific
points in the paper, and the sequences of the oligos used for mapping.
Additional file 9: Table S3. Binding changes at each position along
the Hlx1 binding site caused by a mutated nucleotide. The
Additional material contains maps of all hotspots studied in this paper,
their sequences, additional figures and tables highlighting specific points
in the paper, and the sequences of the oligos used for mapping.
Additional file 10: Figure S7. Effect of Mg2+ on PRDM9-DNA
binding. The Additional material contains maps of all hotspots studied in
this paper, their sequences, additional figures and tables highlighting
specific points in the paper, and the sequences of the oligos used for
mapping.
Additional file 11: Additional experimental procedures: oligos used
for analysis of binding. The Additional material contains maps of all
hotspots studied in this paper, their sequences, additional figures and
tables highlighting specific points in the paper, and the sequences of the
oligos used for mapping.
Additional file 12: Sequences of Prdm9Dom2 and Prdm9Cst cDNA
cloned in pBAD/HisB. The Additional material contains maps of all
hotspots studied in this paper, their sequences, additional figures and
tables highlighting specific points in the paper, and the sequences of the
oligos used for mapping.
Additional file 13: Figure S8. PRDM9 binds to its targets in an
allele-specific manner. The Additional material contains maps of all
hotspots studied in this paper, their sequences, additional figures and
tables highlighting specific points in the paper, and the sequences of the
oligos used for mapping.
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